Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

teriparatide (Rx)Brand and Other Names:Forteo, parathyroid hormone

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

prefilled injectable pen

  • 600mcg/mL (2.4mL)
more...

Osteoporosis

Treatment of postmenopausal women with osteoporosis at high risk for fracture; increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture; treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture

Administer initially while patient is sitting or lying down in the event of orthostasis

20 mcg SC once daily into thigh or abdominal wall

Dosing Modifications

CrCl <30 mL/min: Dose adjustment not necessary; bioavailability and half-life may increase

Osteoporosis (Orphan)

Orphan designation for treatment of idiopathic osteoporosis

Orphan indication sponsor

  • Biomeasure, Inc; 27 Maple St; Milford, MA 01757-3650

Hypoparathyroidism (Orphan)

Orphan designation for treatment of hypoparathyroidism

Orphan sponsor

  • Entera Bio, Ltd; Kiryat Hadassah Minrav Bldg, 5th Floor, P. O. Box 12117; Jeusalem 91220, Israel

Safety and efficacy not established

Next

Interactions

Interaction Checker

teriparatide and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Hypercalcemia (transient increases 4-6 hours after dose; 11% of women, 6% of men)

            1-10%

            Arthralgia (10%)

            Rhinitis (10%)

            Nausea (9%)

            Weakness (9%)

            Dizziness (8%)

            Pharyngitis (6%)

            Dyspepsia (5%)

            Rash (5%)

            Depression (4%)

            Dyspnea (4%)

            Pneumonia (4%)

            Vertigo (4%)

            Antibodies to teriparatide (3% of women in long-term treatment)

            Chest pain (3%)

            Hyperuricemia (3%)

            Leg cramps (3%)

            Syncope (3%)

            Vomiting (3%)

            Tooth disorder (2%)

            Previous
            Next

            Warnings

            Black Box Warnings

            In rats, increased risk of osteosarcoma has been observed; do not prescribe for patients at high risk for osteosarcoma (eg, those with Paget disease, unexplained alkaline phosphatase elevation, open epiphyses, or previous external-beam or implant radiation therapy involving skeleton)

            Contraindications

            Hypersensitivity

            High risk for osteosarcoma

            Cautions

            Hypercalcemia may predispose to digoxin toxicity

            Orthostatic hypotension may occur

            Urolithiasis, bone metastases, metabolic bone disease (other than osteoporosis), open epiphyses, Paget disease, preexisting hypercalcemia

            Use of drug for >2 years during patient lifetime not recommended

            Use caution in cardiovascular disease, renal and/or hepatic impairment, and patients with active or recent urolithiasis

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Safe

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Recombinant human parathyroid hormone; stimulates osteoblast function, increases calcium absorption, and increases renal tubular reabsorption of calcium; these effects lead to increased bond mineral density, bone mass, and strength

            Absorption

            Bioavailability: 95%

            Onset: 3 months

            Peak serum time: Teriparatide, 30 min; calcium, 4-6 hr

            Concentration: Calcium, 9.68 mg/dL

            Distribution

            Vd: 0.12 L/kg

            Elimination

            Half-life: 5 min (IV); 1 hr (SC)

            Total body clearance: Women, 62 L/hr; men, 94 L/hr

            Excretion: Urine

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.